title: The development of combination drugs for atherosclerosis.
abstract: The complexity of medical care has led to a dramatic increase in the number of drugs taken by patients. In an effort to improve patient compliance and the effectiveness of clinical care, many drugs are being studied for combination in a single capsule or tablet. The recent success of many combination drugs for hypertension has accelerated the interest in combination drugs for lipids and atherosclerosis. Advicor (Kos Pharmaceuticals, Miami, FL), a combination of nicotinic acid and a statin (mevacor), is the first combination lipid drug. Recently, the United States Food and Drug Administration approved the combination of another statin, pravachol, with aspirin. Therefore, combination drugs are likely to be a significant contribution to clinical practice and drug development.
authors.affiliation: Global Strategic Regulatory Development, Merck and Company, 126 Lincoln Avenue, Rahway, NJ 07065-0900, USA. donald_black@merck.com
authors.forename: Donald M
authors.initials: DM
authors.lastname: Black
mesh_terms: D001161:Arteriosclerosis / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control; D004359:Drug Therapy, Combination; D006801:Humans; D012307:Risk Factors